// App-Quantinova.ai

3140 : Differential clonal selection in tumor tissue and cell-free DNA from a neratinib-treated refractory breast cancer patient harboring an activating ERBB2 (HER2) mutation

Researchers

Presenter

  • Lars Joenson

Principal Investigators

  • Christina W. Yde

  • Olga strup

  • Morten Mau-Srensen

  • Finn C. Nielsen

  • Ulrik Lassen

Medical Centers

  • Center for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark

  • Department of Hematology, Rigshospitalet, Copenhagen, Denmark

Locations

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Secondary liver cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

  • Erb-B2 Receptor Tyrosine Kinase 3

  • Erb-B2 Receptor Tyrosine Kinase 4

  • Estrogen Receptor 1

  • Human epidermal growth factor receptor 2

  • Serine/threonine-protein kinase mTOR

  • PI3K/AKT

  • Plasma cell-free DNA

Drug/Treatment

  • Fulvestrant

  • Neratinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved